FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:1173-1174 April 11, 2002 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Cohn and Tognoni (Dec. 6 issue)¹ found that the angiotensin-receptor blocker valsartan reduced the combined end point of mortality and morbidity and improved clinical signs and symptoms in patients with heart failure when it was added to prescribed therapy. However, an adverse effect on mortality and morbidity was observed in a subgroup receiving valsartan, an angiotensin-converting–enzyme (ACE) inhibitor, and a beta-blocker. In the overall study, adverse events leading to the discontinuation of valsartan included dizziness, hypotension, and renal impairment, but hypotension was not significantly more frequent in the valsartan group than in the placebo group. The authors . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Johnson, L. L., Schofield, L. M., Weber, D. K., Kolodgie, F., Virmani, R., Khaw, B. A. (2004). Uptake of 111In-Z2D3 on SPECT Imaging in a Swine Model of Coronary Stent Restenosis Correlated with Cell Proliferation. JNM 45: 294-299 [Abstract] [Full Text]